We Work at the Intersection of Innovation and Determination
Every milestone we achieve may provide a patient the possibility of reaching another important milestone in their lives. We understand that every one of these moments matter. It’s with this in mind, that we remain steadfast and focused on discovering, developing and delivering medicines that target the root causes of diseases so that these people may continue to plan and look forward to their future. We honor the resilience and resolve of the sick people who depend on us by continuing to push the boundaries of science.
We Develop Genetic Medicines with Patients as Partners
One simple moment can become truly extraordinary, especially when you’re battling a devastating disease. This is why the Ionis team works tirelessly to discover, develop, and deliver potentially life-transforming medicines for the patients who depend on them. We look to patients to better understand what it means to live with a disease, so our genetic medicines can make the most meaningful contribution to improve their lives.
We Are Transforming the Standard of Care and Pioneering New Markets
As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients. Our broadly applicable, versatile, and rapidly advancing technology platform powers our ability to design targeted medicines to treat rare diseases as well as those that affect millions.
We Are a Force For Life
Ionis is proud of the moments we share to support and uplift one other, as well as our contributions to support equity, diversity and inclusion in everything we do. If you are driven to deliver on the promise of genetic medicines and want to be a force for life to patients seeking more hopeful futures, come join us.
Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information click here to read more.